O
0.233
0.00 (1.39%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | Outlook Therapeutics, Inc. | 看跌 | 看跌 |
AIStockmoo 评分
0.9
| 分析师共识 | 1.0 |
| 内部交易活动 | NA |
| 价格波动 | 0.5 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | -0.5 |
| 平均 | 0.88 |
|
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 38.31% |
| 机构持股比例 | 16.89% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Gilpin Wealth Management, Llc | 31 Mar 2026 | 600,162 |
| Warberg Asset Management Llc | 31 Mar 2026 | 275,000 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 6.00 (Ascendiant Capital, 2,472.90%) | 购买 |
| 中 | 1.00 (328.82%) | |
| 低 | 0.500 (HC Wainwright & Co., 114.41%) | 保留 |
| 平均值 | 2.50 (972.04%) | |
| 总计 | 1 购买, 2 保留 | |
| 平均价格@调整类型 | 0.418 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Ascendiant Capital | 11 Mar 2026 | 6.00 (2,472.90%) | 购买 | 0.434 |
| Chardan Capital | 18 Feb 2026 | 1.00 (328.82%) | 保留 | 0.410 |
| HC Wainwright & Co. | 18 Feb 2026 | 0.500 (114.41%) | 保留 | 0.410 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合